Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025Science Translational Medicine

Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXinyue ZhouSMSteven MoreiraCRCecilia Restelli

Discussion

Loading...

Member takes

Overview

Functional screening reveals AHR modulation improves responses to BET inhibitors in AML, suggesting new therapeutic strategies.

Key Points

  • Activation of the ahr pathway enhances sensitivity to bet inhibitors in acute myeloid leukemia, suppressing myc expression.
  • AHR activation synergizes with bet inhibitors, leading to significant inhibition of leukemia growth in preclinical models.
  • The study identified elmsan1 as a key target involved in histone deacetylation that impacts myc regulation and therapy response.
  • Combining AHR agonists with bet inhibitors effectively reduces leukemia stem cell frequency while sparing healthy blood stem cells.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/689522069f4f1c896c42934chttps://doi.org/10.1126/scitranslmed.adn5400
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of the aryl hydrocarbon receptor eliminates leukemia stem cells in murine models of Acute Myeloid Leukemia2025
  2. 2Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents2025
  3. 3HMGA1 chromatin regulators drive transcriptional networks governing cell cycle progression, immune escape, and menin-inhibitor resistance in KMT2A-r Acute Myeloid Leukemia2025
  4. 4Clone-specific epigenetic regulatory mechanisms in ASXL1-mutant chronic myelomonocytic leukemia2025
  5. 5The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.2025